Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SinoMab Bioscience Ltd. ( (HK:3681) ) just unveiled an update.
SinoMab BioScience Limited announced its audited consolidated annual results for the year ended December 31, 2024, highlighting significant progress in clinical trials and pipeline development. The company’s flagship product, SM03, is in the final review stage for treating rheumatoid arthritis, while SM17 has shown promising results in treating atopic dermatitis. Financially, the company reduced its annual loss by RMB58.0 million, attributed to decreased R&D costs, and raised HKD73.2 million through new share subscriptions. However, the board does not recommend a final dividend for the reporting period.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of novel drugs for treating immunological diseases.
YTD Price Performance: 23.85%
Average Trading Volume: 191,890
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.47B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue